Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 6,000 Shares of Stock

robot
Abstract generation in progress

Jazz Pharmaceuticals Director Bruce Cozadd sold 6,000 shares of JAZZ stock for $1.143 million on April 1, 2026, reducing his position by 1.54%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. The company recently exceeded quarterly EPS estimates with strong revenue growth, and analysts maintain a “Moderate Buy” rating with a target price of $215.38.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin